• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Another Gem for the Biotech Basket

Amid the basket's impressive performance, I'm adding Minerva.
By SHAM GAD Jul 28, 2014 | 12:00 PM EDT
Stocks quotes in this article: NERV, KIN, AVEO, KERX

Back in June, I wrote about building a stock basket of biotechnology stocks. The idea was simple: When it comes to this sector, it's more important to know what you don't know, rather than on focusing on what you do know. The stark truth about biotech stocks is that the majority of them never transform into a business with a commercial product -- and, as a result, they hold no true investment value. In other words, they are purely speculative.

On the other hand, some companies truly do hold promise, and the result is often very skewed to the upside. In my prior article, for instance, I referenced the 230% premium that Merck (MRK) agreed to pay for Idenix Pharmaceuticals (IDIX).

Biotech stocks offer returns that are usually dispersed on both tails of the bell curve, so I suggested that a basket be a sensible approach to investing in these companies. This approach is perhaps more critical than ever now: Last month, the Federal Reserve specially called out biotechs as overvalued, and those comments immediately sent the sector down.

My initial basket is small. While there are dozens of candidates, I wanted to limit the basket to names that have been screened out by other investors -- and are in their portfolios -- or to companies with drug candidates that are in latter stages of the Food and Drug Administration's approval cycle.

Between June 2 and last Friday, the basket has shown impressive results. Kindred Biosciences (KIN) is up approximately 6.5%, Aveo Pharmacueticals (AVEO) has gained 14.7% and Keryx Biopharmaceuticals (KERX) is up nearly 16%.

Today, I'm adding a fourth name to the basket: Minerva Neurosciences (NERV), a small-cap offering candidates for treatment of diseases afflicting the central nervous system. Minerva had its initial public offering several weeks ago at $6 per share. So far the stock has traded tightly, between $5.57 and $7.54. Today, shares trade for just under $7, making for market capitalization of $124 million.

Minerva has two lead candidates that have completed Phase IIa trials, so that fulfills the latter of my two requirements. As for the pre-screened condition, Care Capital owns 3.8 million shares of Minerva, or 21% of the company, after it having bought an additional 737,500 shares at the IPO price of $6. Another group, Index Venture Associates, also owns 2.8 million shares -- 15.4% -- also after an additional IPO purchase of 1.3 million shares.

What's interesting is that both of these investment groups had owned a nice chunk of this company pre-IPO, and that they basically decided to double down and buy more on the public debut. For the general public, shares of Minerva still trade for close to the IPO price.

Again, this basket will be very a selective one, and these decisions will consistently be based on the two conditions I've noted above. Minerva, a very intriguing name, passes both conditions.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Gad was long KIN.

TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

Johnson & Johnson Appears to Be Running Out of Steam

Bruce Kamich
Jun 22, 2022 8:25 AM EDT

The shares of the healthcare giant have been in a long-term uptrend but could break that trend in the weeks ahead.

Anthem's Long-Term Uptrend Is Losing Its Vigor

Bruce Kamich
Jun 22, 2022 7:40 AM EDT

The technical signals of the health benefits provider are weakening.

Here Are 2 Prudent Healthcare Trades

Bret Jensen
Jun 17, 2022 11:30 AM EDT

The country might be heading into recession, but folks still need to get their medicine, good times or bad.

Here's the Level to Zero In on for UnitedHealth Group

Bruce Kamich
Jun 13, 2022 7:29 AM EDT

Shares of the diversified healthcare company have held up fairly well despite the decline in the broader market but soon could be put to the test.

3 Dividend-Paying Healthcare Stocks That Age Well

Bob Ciura
Jun 5, 2022 12:30 PM EDT

Within the next 15 years, people 65 or older are expected outnumber those under 18, for the first time in U.S. history.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:59 PM EDT PAUL PRICE

    Very good quarterly numbers from Bassett Furniture (BSET)

    Bassett Furniture (BSET) blew right through analys...
  • 04:41 PM EDT PAUL PRICE

    First Half Results - Putrid Second Half Results - Likely to Be Much Better

    It's great that we're done with June. 2022 marked...
  • 04:51 PM EDT PAUL PRICE

    We Should Be in for Better Starting Soon

    Window dressing Thursday, the last day of the...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login